Andrew J. Murphy

This profile gathers the share dealings of Andrew J. Murphy in Regeneron Pharmaceuticals, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 16 August 2021 to 14 October 2026, the count stands at 51 filings.

No open-market purchase appears, only 27 sales worth €2.9M. Other entries cover 11 share grants and 9 option exercises. So far in 2026, the count stands at no purchases and 27 sales.

On 15 October 2026 came the latest disclosure, an open-market sale for €131k in Regeneron Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.